title: Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.
authors.forename: Shane M
authors.initials: SM
authors.lastname: Devlin
authors.forename: Brian
authors.initials: B
authors.lastname: Bressler
authors.forename: Charles N
authors.initials: CN
authors.lastname: Bernstein
authors.forename: Richard N
authors.initials: RN
authors.lastname: Fedorak
authors.forename: Alain
authors.initials: A
authors.lastname: Bitton
authors.forename: Harminder
authors.initials: H
authors.lastname: Singh
authors.forename: Brian G
authors.initials: BG
authors.lastname: Feagan
mesh_terms: D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D002170:Canada; D017277:Drug Approval; D005762:Gastroenterology / Q000458:organization & administration*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D012955:Societies, Medical / Q000458:organization & administration*; D013810:Therapeutic Equivalency
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; D000069285:Infliximab; D000068879:Adalimumab